Nature Communications (Mar 2021)

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface

  • Federico Bertoglio,
  • Doris Meier,
  • Nora Langreder,
  • Stephan Steinke,
  • Ulfert Rand,
  • Luca Simonelli,
  • Philip Alexander Heine,
  • Rico Ballmann,
  • Kai-Thomas Schneider,
  • Kristian Daniel Ralph Roth,
  • Maximilian Ruschig,
  • Peggy Riese,
  • Kathrin Eschke,
  • Yeonsu Kim,
  • Dorina Schäckermann,
  • Mattia Pedotti,
  • Philipp Kuhn,
  • Susanne Zock-Emmenthal,
  • Johannes Wöhrle,
  • Normann Kilb,
  • Tobias Herz,
  • Marlies Becker,
  • Martina Grasshoff,
  • Esther Veronika Wenzel,
  • Giulio Russo,
  • Andrea Kröger,
  • Linda Brunotte,
  • Stephan Ludwig,
  • Viola Fühner,
  • Stefan Daniel Krämer,
  • Stefan Dübel,
  • Luca Varani,
  • Günter Roth,
  • Luka Čičin-Šain,
  • Maren Schubert,
  • Michael Hust

DOI
https://doi.org/10.1038/s41467-021-21609-2
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 15

Abstract

Read online

Antibodies targeting the spike protein of coronaviruses are potential candidates for therapeutic development. Here, Bertoglio et al. use phage display to select anti-SARS-CoV-2 spike antibodies from the human naïve universal antibody gene libraries HAL9/10 that block interaction with ACE2 receptor to inhibit infection.